ClinicalTrials.gg
CompletedNCT02277704AtEaseUpdated Jun 20, 2024Results posted

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

A Phase 2 interventional study of TNX-102 SL and Placebo in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Tonix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
178th of 1,491
245 · median 65
Started
2014
with 50 others
Phase 2
168 of 1,664
38 open now
Registered
586th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 178th largest by enrollment of the 1,491 interventional ones that give a count, is one of 51 that started in 2014, is one of 168 in phase 2, and was the 586th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

336 more — sign in →

All 341 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible subjects will return regularly to the study clinic for weekly or biweekly visits for assessments of efficacy and safety.

03

Conditions studied

  • PTSD

Keywords

  • PTSD
  • Military-related PTSD and other related conditions
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 65 years of age
  • Diagnosed with current PTSD as defined by the Clinician-Administered PTSD Scale for (CAPS-5),
  • For patients with a qualifying Index trauma(s) resulting in PTSD that occurred during military service, military contractor, Department of Homeland Security or law enforcement
  • Willing and able to withdraw and refrain from specific therapies (ask PI)
  • Use medically acceptable form of (female only)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Significant traumatic brain injury
  • Severe depression
  • Bipolar and psychotic disorders
  • Increase risk of suicide
  • Significant clinical (cardiac, systemic infection, drug/alcohol abuse) or laboratory abnormalities (including positivity for Hep B, Hep C, )
  • Unable to wash-out specific medications (ask PI)
  • History of violent behavior within past 2 years, unrelated to work duties
  • History of drug or alcohol abuse within past 6 months
  • Positive illegal substance test
  • Known to cyclobenzaprine
  • Others: seizure disorders, uncontrolled sleep apnea, >40
  • Participation in an study in past 30 days
  • In the process of litigating for compensation for a psychiatric disorder
  • Females that are pregnant or breastfeeding
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
245 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    2 x placebo tablet ("placebo") to be taken sublingually once daily at bedtime.

    Drug: Placebo

  • Active comparator
    TNX-102 SL, 2.8 mg

    1 x TNX-102 SL 2.8mg tablet ("TNX-102 SL") and 1 x placebo tablet ("placebo") to be taken sublingually once daily at bedtime.

    Drug: TNX-102 SL · Drug: Placebo

  • Active comparator
    TNX-102 SL, 5.6 mg

    2 x TNX-102 SL 2.8mg tablets ("TNX-102 SL") to be taken sublingually once daily at bedtime.

    Drug: TNX-102 SL

Interventions

06

What researchers measure

Primary outcomes

  1. The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).

    The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.

    Time frame: Day 1, Week 12

Secondary outcomes

  1. Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment

    Change from baseline in patients' quality of sleep using the PROMIS (Patient -Reported Outcome Measurement Information System) Sleep Disturbance scale after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Raw scores are converted to T-scores using published conversion tables. Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance

    Time frame: Day 1, Week 12

  2. Clinician Global Impression - Improvement Scale Responder Rate at Week 12

    Responder rates in CGI-I (Clinician Global Impression - Improvement Scale) after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Responder rate is defined as the number of patients scored as either a 1 or 2 on CGI-I at Week 12. The score ranges from 1 to 7 with the following anchors for each score:1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse

    Time frame: Week 12

  3. Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score

    Mean Change from Baseline in SDS Total Score at Week 12. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.

    Time frame: Day 1, Week 12

07

Results

Posted Jun 20, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
Started9410150
Completed677141
Not completed27309

Outcome measures

PrimaryThe Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).

The mean change from baseline (Visit 2) in the Total CAPS-5 score after 12 weeks of treatment evaluated at Visit 9 (Week 12). The primary efficacy comparison will be the change from baseline in total CAPS-5 score for the 2.8 mg treatment arm compared to placebo. CAPS-5 score ranges from 0-80 with lower scores indicating less severe PTSD symptoms.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).
units on a scalePlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
The Mean Change From Baseline (Visit 2) in the Total CAPS-5 Score After 12 Weeks of Treatment Evaluated at Visit 9 (Week 12).-17.0 ± 1.98-19.2 ± 1.99-21.5 ± 2.41
SecondaryChange From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment

Change from baseline in patients' quality of sleep using the PROMIS (Patient -Reported Outcome Measurement Information System) Sleep Disturbance scale after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Raw scores are converted to T-scores using published conversion tables. Sleep Disturbance T-score ranges from 28.9 to 76.5. Lower scores indicate less sleep disturbance

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment
units on a scalePlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
Change From Baseline in Patients' Quality of Sleep Using the PROMIS Sleep Disturbance Scale After 12 Weeks of Treatment-7.9 ± 1.72-11.1 ± 1.74-11.0 ± 2.10
SecondaryClinician Global Impression - Improvement Scale Responder Rate at Week 12

Responder rates in CGI-I (Clinician Global Impression - Improvement Scale) after 12 weeks of treatment comparing the 2.8 mg treatment arm to placebo. Responder rate is defined as the number of patients scored as either a 1 or 2 on CGI-I at Week 12. The score ranges from 1 to 7 with the following anchors for each score:1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 7=Very much worse

Time frame:
Week 12
Reported as:
Count of participants · Participants
Clinician Global Impression - Improvement Scale Responder Rate at Week 12
ParticipantsPlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
Clinician Global Impression - Improvement Scale Responder Rate at Week 12414831
SecondaryMean Change From Baseline in Sheehan Disability Scale (SDS) Total Score

Mean Change from Baseline in SDS Total Score at Week 12. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.

Time frame:
Day 1, Week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score
units on a scalePlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score-6.4 ± 1.11-7.9 ± 1.11-8.7 ± 1.35

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/94 (0%)3/94 (3.2%)36/94 (38.3%)
TNX-102 SL, 2.8 mg0/101 (0%)0/93 (0%)59/93 (63.4%)
TNX-102 SL, 5.6 mg0/50 (0%)1/50 (2%)35/50 (70%)
Most frequent serious events
Most frequent serious events
EventPlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
ProctitisGastrointestinal disorders0/940/931/50
Perirectal abscessInfections and infestations0/940/931/50
Anaphylactic reactionImmune system disorders1/940/930/50
Multiple sclerosisNervous system disorders1/940/930/50
Suicidal IdeationPsychiatric disorders1/940/930/50
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mg
Hypoaesthesia OralGastrointestinal disorders2/9436/9318/50
paraesthesia oralGastrointestinal disorders3/9415/932/50
Dry mouthGastrointestinal disorders10/944/938/50
SomnolenceNervous system disorders6/9411/938/50
HeadacheNervous system disorders4/945/936/50
SedationNervous system disorders1/942/936/50
InsomniaPsychiatric disorders8/947/933/50
GlossodyniaGastrointestinal disorders1/943/933/50
Abnormal dreamsPsychiatric disorders5/941/931/50
Upper respiratory tract infectionInfections and infestations5/943/932/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mgTotal
Age31.9 ± 6.4834.5 ± 8.1134.7 ± 8.9333.6 ± 7.79
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mgTotal
Female69419
Male889246226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mgTotal
Hispanic or Latino20151146
Not Hispanic or Latino748639199
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTNX-102 SL, 2.8 mgTNX-102 SL, 5.6 mgTotal
American Indian or Alaska Native1304
Asian3115
Native Hawaiian or Other Pacific Islander0000
Black or African American21271260
White616833162
More than one race4105
Unknown or Not Reported4149
08

Study locations

23 sites
  • Tuscaloosa VA Medical Center
    Tuscaloosa, Alabama 35404, United States
  • Noesis Pharma
    Phoenix, Arizona 85032, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • National City
    National City, California 91950, United States
  • Excell Research, Inc
    Oceanside, California 92506, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • CITRIALS
    Riverside, California 92506, United States
  • Veteran Affairs, San Diego Health Care System
    San Diego, California 92161, United States
  • Cns, Inc.
    Torrance, California 90502, United States
  • Sarkis Clinical Trials
    Lake City, Florida 32025, United States
  • Compass Research North, LLC
    Leesburg, Florida 34748, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Atlanta Center For Medical Research
    Atlanta, Georgia 30308, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Novex Clinical Research
    New Bedford, Massachusetts 02740, United States
  • Premier Psychiatric Research Institute, Inc.
    Lincoln, Nebraska 68526, United States
  • Altea Research
    Las Vegas, Nevada 89102, United States
  • Cedarhurst
    Cedarhurst, New York 11516, United States
  • Cincinnati
    Cincinnati, Ohio 45219, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Publications

  • Sullivan GM, Gendreau RM, Gendreau J, Peters P, Peters A, Engels J, Daugherty BL, Vaughn B, Weathers FW, Lederman S. Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res. 2021 Jul;301:113974. doi: 10.1016/j.psychres.2021.113974. Epub 2021 Apr 30. PubMed 33979763 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in May 2016, 19 months.

Results were first posted in Jun 2024, 8 years 1 month after primary completion. A results delay was requested in Oct 2017.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 19 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2014
First posted
Oct 29, 2014
StartActual
Oct 2014
Primary completionActual
May 2016
CompletionActual
May 2016
Results delay requested
Oct 26, 2017
Results first posted
Jun 20, 2024
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02277704
Responsible party
Sponsor
First posted
Oct 29, 2014
Start date
Oct 2014
Primary completion
May 2016
Completion
May 2016
Results posted
Jun 20, 2024
Last update
Jun 20, 2024

Study contacts

Denise Bedoya
study director · Premier Research Group plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclobenzaprine

Start the discussion